The abstract is read at the publisher; the summary is JClub's.
A single infusion of amrecibart or cenvacibart reduced adjudicated venous thromboembolism by day 14 after PICC placement, with 20% vs 43% on placebo.
- Why it matters: PICCs commonly lead to venous thromboembolism, yet no thromboprophylaxis is approved; FXI inhibition may prevent catheter-associated events without increasing bleeding risk.
- What they did: In ROXI-CATH, a double-blind phase 2 trial across 12 centers, adults (≥18) receiving PICCs expected to remain ≥14 days were randomized 1:1:1 to amrecibart 300 mg, cenvacibart 250 mg, or placebo, with ultrasound on days 7 and 14.
- The result: Up to day 14, adjudicated venous thromboembolism occurred in 13/65 (20%) with amrecibart and 13/66 (20%) with cenvacibart versus 27/63 (43%) with placebo, with no major bleeding and similar CRNM bleeding (2/65, 2/66, 2/63).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.